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INTRODUCTION 
Rubella virus. Rubella virus, isolated in 1962 in cell culture by Wei­
ler and N eva and by Pa rkman et al, is an RNA virus. I t  has been de scri­
bed by Best et al (1967) as pleomorphic, but generally spherical, with 
a central nucleoid of 30 nm diameter w ithin an envelop e 60 - 70 nra wi­
de. Lipid is an ess ential part of the envelope and the infectivity of 
the virus is destroyed by ether. Rubella virus multiply in the cyto­
plasm, and are released by budding. Hemagglutinin, one o r more comple ­
ment-fixing antigens, and two pr ecipit inogens, theta and iot a are 
structural components o f the purified intact virion. Only one se rologi­
cal type of rubella virus has been de scribed. On the basis of i ts phy­
sical and chem ical characteristics rubella virus has been c lassif ied 
as belonging to the Alpha vi rus genus of the Toga vi rus family. 
Rubella antibody tests. The i solation of rubella virus in cell cultures 
was ra pidly followed by th e development o f techniques to detect serum 
antibodies to the virus by n eutralization tests (Parkman et al 1964). 
Neutralizing (NT) antibodies develop a fter rubella infection and per­
sist probably l i fe-long. The ex istence of NT antibo dies could be sho wn 
to protect against clinical infection, thus indicating immunity 
(Schiff et al 1965). In 1967 the hemagglutinating abil i ty of rubella 
virus was demons trated and antibod ies to the virus could be detected 
by hemaggluti nation-inhibit ion (HI) tests (Stewart et al 1967, Halonen 
et al 1967). Pre-treatment of serum with either kaolin (Stewart et al 
1967, Halonen et al 1967), heparin and M nClg (Feldman 1968) or dextran-
sulfate and CaC^ (Liebhaber 1970) is necessary for removal of the 
nonspecific inhibitors normally present in serum. The HI technique i s 
now i n general use f or diagnosis of rubella and fo r determination of 
immunity since i t  is more ra pid and easier to perform than the NT t est. 
However, the presence o f NT antib odies is considered a more re liable 
indication of immunity. Testing for complement-fixing antibodies is of 
value only for the diagnosis of recent infection. Immunofluorescence 
techniques are available for determination of antibodies (Lennette et 
al 1967), but are not in general use. In 1975 a new techn ique, hemo-
- .»lysis-in-gel (HIG), was described for detection of rubella antibodies 
(paper V, Skaug et al 1975). 
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Rubella infection. At the International Congress of Medicine in London 
in 1881 rubella was dis tinguished from scarlet fever and m easles and 
described-as a distinct and sp ecific entity (Squire 1881). Veale d esri-
bed in 1866 30 cases from an epidemic and propose d the name r ubella. 
The p ostnatal rubella disease is characterized by mi ld upper re spira­
tory symptoms, fever, glandular swelling and rash. The most co mmon 
complication of rubella is arthralgia and a rthritis which occur in mo­
re than 50% of adult women bu t less frequently in children and m en 
(Banatvala 1972). Encephalitis and thrombocytope nia are other, less 
common, complications of the disease. The c linical symptoms are vari­
able and su bclinical infections are common. A ra te of 2:1 for subcli­
nical to apparent infection was found i n an epidemic by Horstmann et 
al (1970b) .Thus, a c orrect diagnosis can only be est ablished by sero­
logical tests. 
The disease was considered as a harmless exanthematous disease of 
childh.ood u ntil 1941 when Gr egg described the association of rubella 
infection during early pregnancy and conge nital cataract and hear t di­
sease. The c haracteristic feature of congenital rubella is the multi­
plicity of defects seen, the most fre quent being ocular, cardiac' and 
hearing defects, microcephaly, mental and growth r etardation and the 
chronic persistence of fetal infection. Neonatal manifestations of 
the rubella syndrome are failure to thrive, thrombocytopenic purpura, 
hepatitis with jaundice and hepato- and splen omegaly (Cooper et al 
1969). The r isk of fetal damage i s highest during the first eight 
weeks of pregnancy, w ith a sharp d ecline in incidence after the 20th 
week, although evidence o f deafness and m ental retardation after in­
fection between the 20th and 24th weeks o f pregnancy wa s found by 
Hardy et al (1969). Dudgeon (1970) quoted an overall incidence of da­
mage o f 30-40% for rubella infection during the first trimester. Du­
ring a large epidemic o f rubella in the United States in 1964 1% of 
all pregnancies were rubella-damaged and mor e than 25 000 children 
were born with congenital rubella (Cooper 1972). This epidemic emp ha­
sized the rubella problem and in it iated intensive research work aimed 
at the development of rubella vaccines. 
Rubella vaccines. The first effective vaccine strain, HPV-77 wa s de­
veloped by Meyer et al (1966) and had been attenu ated by 77 passages 
in green mo nkey kidney (GMK) cells. This strain was f urther attenuated 
by five passages in duck embryo c ells, HPV-77 DE-5, and w as i n preli-
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minary  t r i a l s  shown t o  induce  a  s a t i s f ac to ry  se ro log ica l  r e sponse  wi th  
an  accep tab le  inc idence  o f  s ide -e f fec t s  (Buynak  e t  a l  1968) .  The  H PV-77  
s t r a in  was  a l so  passaged  i n  dog  k idney  c e l l  cu l tu res ,  HPV-77  DK-12 ,  bu t  
has  r ecen t ly  been  wi thdrawn  f rom the  marke t  because  o f  a  h igh  inc idence  
o f  j o in t  symptoms .  
The  Cendeh i l l  s t r a in  was  deve loped  by  Huyge len  and  Pee te rmans  (1967)  
and  was  used  a f t e r  the  51s t  passage  in  p r imary  r abb i t  k idney  c e l l s .  
The  RA 27 /3  s t r a in ,  f i na l l y ,  was  deve loped  a t  the  Wis ta r  i n s t i t u t e  in  
Ph i l ade lph ia  (P lo tk in  e t  a l  ]967)  and  t he  29 th  passage  l eve l  i n  Wis ta r  
38 ,  human  d ip lo id  ce l l s ,  was  used  a s  vacc ine .  Al l  t h r ee  vacc ine  s t r a ins  
a re  in fec t ious  and  immu nog en ic  by  t he  subcu taneous  r ou te  bu t ,  i n  add i ­
t ion ,  the  R A 27 /3  s t r a in  was  shown t o  be  immu nogen ic  a l so  a f t e r  i n t ra ­
nasa l  admin i s t r a t ion  (P lo tk in  e t  a l  1968) .  
Vacc ina t ion  p rograms .  At  l e a s t ,  two  d i f f e ren t  p rogr ams  a r e  in  use  f o r  
the  p reven t ion  o f  rube l l a  du r ing  p regnancy .  In  t he  Uni t ed  S t a t es  the  
a im o f  ac t ive  immuniza t ion  has  been  t o  r educe  the  inc idence  o f  rube l l a ,  
thus  t o  p ro tec t  p regnan t  wom en  f ro m in fec t ion  in  the  communi ty .  Th i s  
p rog ram invo lves  the  vacc ina t ion  o f  a l l  ch i ld ren  be tween  t he  ages  o f  
1  and  11  yea rs  i n  o rde r  t o  induce  so -ca l l ed  "he rd  immuni ty" .  In  t he  
Uni t ed  Kingdom an d  man y  o t he r  European  coun t r i e s ,  i nc lud ing  Sweden ,  
t he  p r inc ipa l  a im o f  vacc ina t ion  has  been  t o  ensure  t ha t  women  a r e  in ­
d iv idua l ly  immune  t o  rube l l a  when  r each i ng  ch i ldbea r ing  age  by  t h e  
vacc ina t ion  o f  ado lescen t  g i r l s .  
These  two  d i f f e ren t  p rograms  a l so  inc lude  recommenda t ions  fo r  the  vac ­
c ina t ion  o f  ce r t a in  ca tegor i e s  o f  adu l t  women  w ho  hav e  been  sho wn to  
be  su scep t ib l e  to  rube l l a  by  p r io r  se ro log ica l  t e s t ing .  S ince  l ive  
a t t enua ted  vacc ine  v i rus  may  ex h ib i t  t he  t e ra togen ic  p rope r t i e s  o f  
rube l l a  v i rus ,  vacc ina t ion  o f  adu l t  w omen  can  on ly  be  pe r fo rmed  i f  
the  wom an  i s  no t  p regnan t  a t  the  t ime  o f  vacc ina t ion  and  wi l l  no t  be ­
com e  p regnan t  fo r  a t  l eas t  two  m onths  a f t e rwards .  Thus ,  mass  vacc ina ­
t ion  o f  adu l t  wom en  w i l l  be  d i f f i cu l t  t o  pe r fo rm s in ce  even  wi th  the  
p resen t  l imi t ed  p rograms  t he re  a re  seve ra l  r epor t s  o f  i nadver t en t  vac ­
c ina t ion  in  p regnancy ,  some  o f  which  have  been  a s soc ia t ed  wi th  r ecove­
ry  o f  vacc ine  v i ru s  f rom f e t a l  t i s sue  and  p roduc t s  o f  concep t ion  
(Ph i l l i p s  e t  a l  1970 ,  Vaher i  e t  a l  1972 ,  Wyl l  and  Her r mann  1973 ,  F lee t  
e t  a l  1974) .  To  c i r cumven t  t h i s  p rob lem vacc ina t ion  dur ing  the  pos t r  
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par tum pe r iod  o f  suscept ib l e  women  has  been  used  and  i s  recommended  i n  
Sw eden  a s  a  complement  t o  the  vacc in a t ion  o f  ado lescen t  g i r l s .  
Backgroun d  t o  the  p resen t  s tud y .  Up  t o  1972 ,  when  t h e  p resen t  s tudy  
s t a r t ed ,  no  obv ious  d i f fe rences  be tween  th e  th ree  ava i l ab le  vacc ines  
in  se roconve r s ion  r a t e s  and  t r ans miss ib i l i t y  to  con tac t s  had  been  de ­
mons t ra t ed .  Howev er ,  t he re  were  i n d ica t ions  tha t  d i f f e rences  in  an t i ­
body  t i t e r s  a f t e r  vacc ina t io n  ex i s t ed  (D udge on  e t  a l  1969 ,  Foge l  e t  a l  
1971 ,  Tob in  1971) ,  w i th  a  h ighe r  HI  an t ibody  re sponse  induced  by  t h e  
RA 27 /3  s t r a in  in  compar i son  wi th  the  Cendeh i l l  s t r a in .  Neu t r a l i z ing  
an t ibod i es  had  on ly  been  s tud ied  in  sma l l  g roups  and  had  no t  inc luded  
a l l  th r ee  vacc ines  (Foge l  e t  a l  1971 ,  Tob in  1971) .  
S ide -e f fec t s  were  found  more  o f t e n  in  adu l t  women  t han  in  ado le scen t  
g i r l s  and  ch i ld r en  (Weibe l  e t  a l  1972) .  In  adu l t  women  j o in t  symptoms  
had  been  show n t o  occur  i n  a s  m any  a s  40% a f t e r  vacc ina t io n  wi th  the  
HPV-77  s t ra ins  (Weib e l  e t  a l  1969)  and  10% a f t e r  immuniza t ion  wi th  the  
Cendeh i l l  s t r a in  (Hors tmann  e t  a l  1970  a ) .  Di rec t  compara t ive  t r i a l s  o f  
t he  Cendeh i l l  and  RA 27 /3  vacc ines  i n  adu l t  women  (Du dgeon  e t  a l  1969 ,  
Foge l  e t  a l  1971 ,  Tob in  1971)  somet imes  showed  l i t t l e  d i f fe rence  in  
the  inc idence  o f  j o in t  symptoms  wh i l e  i n  o the r s  RA 27 /3  gave  some wha t  
more  j o in t  r eac t ions .  However ,  l a rge r  compara t ive  s tud ies  in  adu l t  wo­
men  inc lu d ing  a l l  t h ree  vacc ine  s t r a ins  were  l ac k ing  bo th  conce rn in g  
an t ibody  t i t e r  re sponse  and  s ide -e f fec t s .  
The  du ra t ion  o f  immuni ty  induced  by  ru be l l a  vacc ina t ion  i s  no t  s a t i s ­
f ac to r i ly  know n.  As  t he  main  g roup  i n  many  vacc ina t ion  p rograms  con­
s i s t s  o f  ch i ld ren  and  ado lescen t  g i r l s  the  immuni ty  induced  by  v acc in a ­
t ion  shou ld  have  a  du ra t ion  o f  a t  l eas t  20  yea rs  t o  p ro tec t  aga ins t  f e ­
t a l  in f ec t ion  dur ing  a  fu tu re  p regnancy .  Ano the r  cause  o f  conce rn  abou t  
t he  impac t  o f  rube l l a  vacc in a t ion  was  t he  h igh  r e in fec t ion  r a t e ,  50-80% ,  
found  in  vacc inees  bo th  a f t e r  cha l l enge  (Meye r  e t  a l  1968 ,  Sch i f f  e t  
a l  1969 ,  Wi lk ins  e t  a l  1969)  and  a f t e r  exposure  in  rube l l a  ep idemics  
(Wi lk ins  e t  a l  1969 ,  Chan g  e t  a l  1970 ,  Hors tmann  e t  a l  1970  b ,  Dav i s  
e t  a l  1971) .  Re in fec t ions  a re  kn own t o  occur  in  ind iv idu a l s  wi th  na tu ­
r a l ly  acqu i red  immuni ty  bu t  a t  a  much  lower  r a te ,  3 -10%,  (Meye r  e t  a l  
1968 ,  Hors tmann  e t  a l  1969 ,  Pa rkman  1969) .  These  f ind ings  emphas ized  
the  impor tance  o f  a  vacc ine  which  induced  an  immune  r e sponse  a s  c lose  
a s  poss ib le  t o  tha t  o f  na tu ra l  i n fec t ion  (Ho rs tmann  1971) .  
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Rube l l a  vacc ina t ion  o f  adu l t  women  on  a  l a rge  sca le  necess i t a t e s  the  
use  o f  a  s a f e  and  r ap id  se ro log i ca l  t echn ique  fo r  the  de te rmina t ion  o f  
rube l l a  immuni ty .  In  the  H I  t e s t  the  nonspec i f i c  i nhib i to r s  normal ly  
p resen t  i n  se rum cause  some  p rob le ms  and  l ead  to  uncer t a i n ty  abou t  t he  
va lue  o f  low an t ibody  t i t e r s .  In  1974  Bea le  r epor t ed  a  s ing le  r ad ia l  
hemolys i s  t echn ique  fo r  de tec t ion  o f  an t ibod ie s  to  hemagg lu t ina t ing  
v i ruses  and  t h i s  me thod  had  been  app l i ed  to  in f luenza  v i rus  (Russe l  e t  
a l  1975)  bu t  seemed  a l s o  app l i cab le  t o  rub e l la .  
9 
AIM OF THE PRESENT INVESTIGATION 
One purpose of the present study was to compare the three available 
rubella vaccines considering immunogenicity and adverse reactions af­
ter vaccination of newly delivered women by the investigation of 
1. the serological response eight weeks and two years after vacci­
nation. 
2. the immunity to intranasal challenge two years after vaccination. 
3. the incidence of side-effects after vaccination. 
Due to the fact that vaccination was carried out during the postpartum 
period it was also important to consider 
4. the possibility for transmission of vaccine virus to the babies 
of vaccinated mothers. 
5. the influence of anti-D immunoglobulin and blood transfusion on 
the serological response. 
Finally, one purpose of the study was 
6. to evaluate a new technique,hemolysis-in-gel, for determination of 
immunity to rubella. 
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MATERIALS AND M ETHODS 
Patients 
During 1972 newly d elivered women i n Göteborg, who ha d no or low H I an­
tibody titers, were offered vaccination against rubella. Three groups 
of patients were in cluded in the study. One, a non-immune group , con­
sisted of women w ith pre-immunization HI antibody titers of 10 or less. 
Of the two other groups one wa s composed of vaccinees with pre-immuni­
zation titers of 20 and the other consisted of women w ith titers of 40 
or more. All pregnant women were tested for immunity a gainst rubella 
at their first visit to an an tenatal clinic or to their private physi­
cian. The vaccination was performed within four days postpartum a t the 
obstetric department. To avoi d a new pregnan cy contraceptives were used 
for three months following vaccination. Blood samples were o btained 
from 872 women before vaccination and then six weeks or later (mean 
eight weeks) after the vaccination. 143 rubella vaccinated women were 
followed up by taking a third blood sample a fter two years and 99 of 
these women were rev accinated intranasally. The result of the revacci­
nation was t ested by a new blood sample a fter another six weeks. 
The incidence of side-effects after vaccination was evalua ted in 949 
women by m eans o f a questionnaire and in a number o f cases by c linical 
examination. Also, blood samples were ob tained from 63 babies of vac­
cinated mothers d uring routine examination at the infant welfare cli­
nics, usually at the age of two to eight months. 
Vaccines 
Three d ifferent vaccines were used througho ut the study: the Cendehill 
(Cendevax, Sm ith, Kline and French l aboratories], HPV-77 DE- 5 (Meruvax, 
Merck, Sharp and Do hme), and RA 27/3 (Almevax, Burroughs Wellcome) vac­
cine strains. The vaccines contain live attenuated rubella virus and 
differ from each other with regard to the type of cells and pass age 
level used f or attenuation. 
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Al l  t h r ee  vacc ines  were ,  a f t e r  r econ s t i tu t ion ,  admin i s t e red  subcu taneo-
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us ly  in  a  dose  o f  0 .5  ml ,  con ta in ing  a t  l eas t  10  TCID 50 .  For  r evacc i ­
na t ion  by  t h e  in t rana sa l  rou te  the  RA 27 /3  s t r a in  was  used  and  each  i n -
4  t r anasa l  dose  con ta ined  a t  l eas t  10  TCID 50  o f  t he  a t t enua ted  v i rus  
s t r a in .  Th e  i n t ranasa l  vacc ina t ion  was  pe r fo rmed  wi th  the  pa t i en t  i n  
the  sup ine  pos i t ion  wi th  he r  head  unsuppor t ed  and  hyperex tended  and  
0 .25  ml  o f  t he  r econs t i tu t ed  vacc ine  was  d ropped  in to  each  nos t r i l .  Af ­
t e r  admin i s t r a t ion  o f  t he  dose  t h i s  pos i t ion  was  ma in ta ined  fo r  a t  
l eas t  one  minu te .  
Se ro logy  
Serum sample s .  Se ra  were  i n ac t iva ted  and  s t o red  a t  -20°C un t i l  t e s t ed .  
Al l  s e r a  f rom one  and  the  same  pa t i en t  were  a lways  run  in  pa ra l l e l .  
Def in i t ion s .  Us ing  HI  o r  the  N T t e s t  an  a t  l eas t  fou r fo ld  inc rease  in  
t i t e r  be tween  p a i r ed  samples  was  c ons ide red  s ign i f i c an t .  Se roconver s ion  
was  d e f ined  a s  a  t i t e r  d i f f e rence  o f  two  o r  more  t i t r a t i on  s t eps  be t ­
ween  p re  and  pos t - immuniza t ion  se rum samples .  For  ev a lua t ion  o f  r e su l t s  
wi th  the  HIG t e s t  see  pape r  VI .  
Re in fec t ion  o r  boos te r  r e sponse  was  d e f ined  a s  a  s ign i f i c an t  t i t e r  r i ­
se  in  HI  an t ibod ies  be tween  pa i r ed  se rum samples .  
Mean  t i t e r s  a re  g iven  a s  geomet r i c  mea n  (G MT)  fo r  HI ,  a s  median  t i t e r s  
fo r  N T an d  a s  the  mea n  d i amete r  (mm )  o f  hemoly t i c  zones  i n  the  HIG 
t e s t .  
Hemagg lu t ina t ion - inh ib i t ion  t e s t .  The  H I  t echn ique  deve loped  by  Ha lon en  
e t  a l  (1967)  was  used  wi th  s l igh t  modi f i ca t ion s .  P igeon  e ry th rocy tes  
were  empl oyed  and  s e ra  were  adso rbed  on  kao l in  (Schmid t  1970) .  An  HI  t i ­
t e r  o f  20  o r  more  was  cons ide red  to  ind ica te  immuni ty .  
Neu t ra l i za t ion  t e s t .  Conven t iona l  t echn ique  wa s  used  f o r  N T an t ibody  
as say  and  t he  p rocedure  i s  desc r ibed  in  de ta i l  i n  pape r  I I I .  Twofo ld  
se rum d i l u t ions  f rom 1 /2  to  1 /16  were  t e s t ed  fo r  inh ib i to ry  e f f ec t  on  
t he  cy topa th ic  changes  o f  rube l l a  v i rus  on  RK^  ( r abb i t  k idney  c e l l  
l i ne )  tube  cu l tu res  (Furesz  1969) .  To  enhance  th e  neu t ra l i z ing  capac i ­
ty  4 % unhea ted  g u inea -p ig  se rum was  added  t o  the  d i l uen t  used  f o r  se ra  
(Lee rh0y  1968a) .  A N T t i t e r  o f  2  was  c ons ide red  to  ind ica te  immuni ty  t o  
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rubella. 
Hemolysis-in-gel test. The HIG te st is based on the principle that e-
rythrocytes coated w ith antigen will be ly sed by comp lement i n the pre­
sence o f specific antibodies. The following procedure wa s used for per­
formance of the test. (Details are given in papers V and V I). 
Erythrocytes (RBC), collected in Alsevers solution, were washed 3-6 t i­
mes in phosphate b uffered saline (PBS) before incubation with antigen. 
Pigeon ery throcytes were used i n most experiments, but in addition 
sheep, goose, ox o r human group 0 RBC we re tested. For coating of RBC 
300 hemagglutinating units (HAU) of rubella HA anti gen (Wellcome la bo­
ratories) were used per 25^ul of a 50% RBC suspension. Antigen-coated 
RBC we re mixed thoroughly with 1.6% agarose (Behringwerke) or 1.5% In-
dubiose A-37 (L'Industrie Biologique Française) at a temperature of 
47°C and poured onto Petri dishes placed on a level surface. After so­
l idification 3 mm holes were punched o ut in the gel and 5^ul of serum 
or serum di lutions was add ed t o the holes. After diffusion of serum 
at +4°C normal guinea-pig serum w as poured onto the plates which were 
incubated at 37°C f or 2 hours. Unless othe rwise stated, a d iffusion 
time of 24 hours was used. The diameter of the hemolytic zones was m ea­
sured w ith precision calliper to the nearest 0.1 mm. Two perp endicular 
diameters were mea sured f or each zone and the mean o f these values was 
recorded. A diameter of 6 mm or more w as considered to indicate immu­
nity to rubella. 
Statistical methods 
Standard m ethods were used f or calculation of mean values and standard 
deviations. Values of P<0.05 were considered to be s ignificant. The 
chi-square method wa s used to test differences. Statistical comparison 
between m ean t iters in paper I  was performe d by u sing the method tr end 
in a contingency table. Regression li nes (paper VI) were calculated 
from r esults of 6 replicates for each a ntibody concentration by the 
method of least squares. 
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RESULTS 
Se ro log ica l  r e sponse  a f t e r  rube l l a  vacc ina t ion  
872  w omen  wer e  vacc ina te d  wi th  the  Cendeh i l l ,  HPV-77  DE-5 ,  and  RA 27 /3  
vacc ines .  The  vacc inees  were  g rouped  accord ing  to  the i r  immun e  s t a tus  
and  511  were  found  to  l ack  rube l l a  HI  an t ibod ie s  whereas  361  had  HI  t i ­
t e r s  o f  20  o r  more  be fo re  vacc ina t ion .  The  s e ro l og ica l  r e sponses  indu­
ced  by  t h e  th ree  d i f f e ren t  vacc ines  were  compar ed .  In  a l l  w omen  H I  an ­
t ibod ies  were  de te rmined  be fo re  vacc ina t ion  and  a f t e r  e igh t  weeks  and  
143  women  we re  r e t e s t ed  a f t e r  two  yea r s .  
NT an t ib od ie s  were  de te rmined  in  se rum samples  f rom 111  w omen  a f t e r  
e igh t  weeks  and  f rom 70  women  two  yea r s ,  l a t e r .  The  an t ibody  re sponse  
in  55  women  was ,  i n  add i t ion ,  eva lua ted  by  t h e  HIG t echn iqu e .  
Hemagglu t ina t ion - inh ib i t ion  an t ibody  re sponse  (pape r s  I  and  IV) .  In  
suscep t ib le  women  t he  se roconver s ion  r a t es  were  91% in  Cendeh i l l ,  92% 
in  HPV-77  DE- 5  and  96% in  R A 27 /3  vacc inees  (Tab le  I ) .  The  d i f f e rences  
in  se roconver s ion  r a t e s  obse rved  wi th  the  th ree  vacc ines  were  no t  s t a ­
t i s t i ca l ly  s ign i f i can t .  The  me an  t i t e r s  seen  a f t e r  vacc ina t ion  o f  non­
imm une  wo men  we re  32  in  the  Cendeh i l l ,  39  i n  the  HPV-77  DE -5  and  51  in  
the  RA 27 /3  g roup .  These  d i f f e rences  were  s i gn i f i can t  (P  <  0 .01 ) ,  sug­
ges t ing  tha t  the  R A 27 /3  vacc ine  was  more  imm uno genic  t han  HPV-77  DE-5 ,  
t he  l a t t e r  be ing  in  tu rn  mo re  e f f ec t ive  than  the  Cendeh i l l  s t r a in .  In  
t he  two  g roups  o f  im mune  wo men  l e s s  than  10% r e sponded  to  vacc ina t io n  
wi th  a  s ign i f i c an t  t i t e r  r i s e .  In  these  vacc inees  a  doub l ing  o f  t he  
p re - immuniza t ion  t i t e r s  was  a s  a  ru l e  seen .  
Tab le  I .  HI  an t ibody  re sponse  t o  rube l l a  vacc ina t ion  in  se ronega t i ve  
wom en  
No  o f  Se roconver s ion  Geomet r i c  
Vacc in e  s t r a in  wom en  No  % mean  t i t e r  
Cendeh i11  210  192  91  32  
HPV-77  DE-5  182  168  92  39  
R A 27 /3  119  114  96  51  
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In  the  major i ty  of  the  143  vacc inees  s tudied  the  HI  t i t e r s  a f te r  two 
years  were  wi t h in  -  one  t i t r a t ion  s tep  of  the  t i t e r s  found  e igh t  weeks  
a f te r  vacc ina t ion .  The  m ean  t i t e r s  in  th i s  group  of  women were  32  fo r  
Cendehi11 ,  36  fo r  HPV-77  DE- 5  and  59  fo r  R A 27 /3  vacc inees  a t  e igh t  
weeks  pos tvacc ina t ion  compared  to  33 ,  56  and  48 ,  respec t ive ly ,  two 
years  l a te r .  Al though  no  genera l  decrease  in  an t ibody  t i t e r s  could  be  
demons t ra ted  i t  should  be  observed  tha t  th ree  women in  the  Cendehi11  
group  had  HI  t i t e r s  less  than  10  a f te r  two yea rs .  Al l  th ree  had  p re ­
v ious ly  responded  t o  vacc ina t ion  by  fo rmat io n  of  HI  an t ibodies .  
Neut ra l iz ing  an t ibody  response  (paper  I I I ) .  I n  a  gr o u p  o f  1 1 1  w o m e n ,  
who  had  responded  wi th  se roconvers ion  accord ing  to  the  HI  t es t ,  on ly  
56% of  Cendehi11  compared  to  79% of  HPV-77  DE- 5  and  95% of  RA 27 /3  
vacc inees  had  deve loped  NT an t ib odies  e igh t  weeks  a f te r  vacc ina t ion  
(Table  I I ) .  However ,  two ye ars  l a te r ,  when  70  women were  r e t es ted ,  82 ,  
94  and  100%,  respec t ive ly ,  o f  the  vacc inees  had  N T t i t e r s  of  2  o r  more  
S ta t i s t i ca l  compar i sons  revea led  tha t  the  d i f fe rences  in  NT an t ibody  
response  seen  a t  e igh t  weeks  and  two years  pos tvacc ina t ion  be tween  RA 
27 /3  and  Cendeh i l l  vacc inees  were  s ign i f icant  (p  <  0 .05) .  Between  the  
R A 27 /3  and  the  HPV-77  DE- 5  g roups  a  s ign i f icant  d i f fe rence  was  found  
on ly  in  se ra  co l lec ted  a f te r  e igh t  weeks .  This  was  a l so  the  case  when  
HPV-77  DE-5  and  Cendeh i l l  vacc inees  were  compared .  
The  N T an t ibody  t i t e r s  induced  by  va cc ina t ion  were  ge nera l ly  low.  The  
median  t i t e r  for  the  Cendehi l l  g roup  was  2  compared  to  4  in  the  o ther  
two g roups .  Af te r  two ye ars  the  median  t i t e r s  had  in creased  to  4 ,  8  
and  8 ,  respec t ive ly ,  bu t  the  d i f fe rence  in  response  be tween  Cendehi l l  
vacc inees  and  the  two o th er  groups  pe rs is ted .  In  a  compar i son  be tween  
HI  and  NT an t ibody  t i t e r s  i t  could  be  show n tha t  in  20  ou t  o f  61  women 
Table  I I .  Neut ra l iz ing  an t ibody  response  8  weeks  and  2  years  a f te r  
rube l l a  vacc ina t ion  
8  weeks  2  yea rs  
Vacc ine  s t ra in  No t e s ted  % t i t e r  No t e s ted  % t i  t e r  
Cendehi11  24 /43  56  2  27 /33  82  4  
HPV-77  DE-5  23 /29  79  4  16 /17  94  8  
RA 27 /3  37 /39  95  4  20 /20  100  8  
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a s ignificant t iter rise in NT an tibodies was demonstra ble during the 
follow-up period while only 6 of these wo men sho wed a fourfold rise in 
HI antibodies (P < 0.001). 
Antibody response determined w ith the hemolysis-in-gel test (paper VI). 
Fifty-five women, vaccinated against rubella and tes ted by HI and N T 
before vaccination and eig ht weeks and two years afterwards were also 
studied by the HIG t est. All had sh own seroconv ersion by developm ent 
of HI antibodies at eight weeks after the vaccination. Fifty-two women 
(95%) were then found to be p ositive in HIG co mpared t o 72% demonstra­
ting NT an tibodies. Two years after vaccination all except one w omen 
had antib odies demonstrable by HIG wh ile 8% sti l l lacked NT an tibodies. 
In two wo men th e HI t iters had by then decreased t o less than 20. 
Immunity to intranasal challenge 
A high reinfection rate has been repor ted in Cendehill and HPV-77 DE-5 
vaccinees (Wilkins et al 1969, Chang et al 1970, Horstmann et al 1970 b, 
Davis et al 1971) but a lower rate was in dicated in RA 27/3 vaccinees 
(Liebhaber et al 1972). Reinfection occurs in 3-10% of naturally immu­
ne in dividuals and is probably of importance f or maintenance o f immu­
nity (Horstmann 1971). However, since reinfection during pregnancy has 
been asso ciated with transmission to the fetus (Northrop et al 1972, 
Eilard and Strannegård 1974 ) the high reinfection rate seen in vacci­
nees has cause d concern. The pre sent study offered a p ossibil ity to 
compare the resistence to reinfection induced by the three vaccines 
(paper IV). 
Two years after the primary vaccination a c hallenge by intranasally 
administered virus was performed. As challenge virus the RA 27/3 strain 
was used. HI antibody titers were determined befor e and si x weeks af­
ter challenge. Ninety-nine women were inc luded in the study and of the­
se 38 had re ceived the Cendehill, 29 the HPV-77 DE-5 and 32 the RA 
27/3 vaccine. A respon se to challenge with a s ignificant t iter rise 
was taken as an indication of susceptibil i ty to reinfection. 
In the Cendehill group 53% were found to be su sceptible compared to 
24% in the HPV-77 DE -5 (Table III). In contrast to these results only 
9% of RA 27/3 vaccinees demonstrated a significant t iter rise after 
challenge. The d ifference in susceptibil ity to challenge between 
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Table I II. HI antibody titer response after intranasal challenge with 
the RA 27/3 strain two years after rubella vaccination 
Vacci ne No o f 
women 
I  titer 
ri ses 
GMT 
Before After 
challenge challenge 
Cendehi11 
HPV-77 DE -5 
RA 27/3 
38 
29 
32 
53 
24 
9 
33 
55 
46 
117 
99 
59 
RA 27/3 vaccinees and Cendehill was s tatistically significant 
(P < 0.001) as also was that between the latter and the HPV-77 DE -5 
group (P < 0.03). As shown i n Table II I,  intranasal challenge did not 
significantly influence the mean t iter in the RA 27/3 group wh ile in 
the other two groups mark ed incr eases were demons trable a fter revacci­
nation. The s usceptibil ity to intranasal challenge was found to be re ­
lated to the antibody level induced by primary vaccination. Thus, the 
mean t iter after two yea rs, before challenge, was 25 in the susceptib­
le group compared to 54 in the group o f women wh o d id not show an y 
booster response upon cha llenge. 
Side-effects were studied in 949 women o f whom 280 had receive d the 
RA 27/3, 332 the Cendehill and 337 the HPV-77 DE -5 vaccin e (paper I). 
The r eactions seen a fter vaccination were r ubella-like symptoms l i ke 
fever, glandular swelling, sore throat, rash and j oint symptoms inclu­
ding both arthritis and ar thralgia. Fever, glandular swelling, sore 
throat and rash appeared betw een the 7th and the 12th day a fter vacci­
nation and u sually had a duration of three to four days. The onset of 
joint symptoms was gen erally later than that of other side-effects and 
in most cases they were f irst noticed two weeks , in some vaccinees as 
late as four weeks, after vaccination. The d uration was als o longer 
but did not usually exceed one week . However, in the HPV-77 DE -5 group 
a few wo men experienced persistent arthritis for as l ong as two mo nths 
and on e of them s ti l l has re current joint symptoms a fter three years. 
Side-effects of rubella vaccination 
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One or more reactions were experienced by 34% of the vaccinees in the 
RA 27/3 group, by 23% in the Cendehill group and by 44% in the HPV-77 
DE-5 group. The differences between the groups are all statistically 
significant (P < 0.03). Local reactions at the site of injection were 
rarely seen except in the RA 27/3 group, in which 18% of the vaccinees 
noticed erythema and swelling compared to 3% and 2% in the other two 
groups (P < 0.001). Fever and glandular swelling occurred in 3 to 9% of 
the vaccinees and no differences between the groups were found. Sore 
throat, rash and joint symptoms, on the other hand, occurred signifi­
cantly more often in the HPV-77 DE-5 group (P < 0.005) and were seen in 
17, 20 and 32%, respectively, of the vaccinees compared to between 7 
and 11% in the other two groups. A comparison between the RA 27/3 and 
the Cendehill group revealed no certain differences except for local 
reactions and the total number of side-effects. 
However, since side-reactions could be expected to occur more often in 
seronegative than in previously immune women the incidence of joint 
symptoms and rash was evaluated according to the serological pre-immu-
nization status. As may be seen from Table IV, these two side-effects 
were more common among susceptible women and the differences were sta­
tistically significant for all except joint symptoms in the Cendehill 
group (P < 0.05). A comparison between the latter and the RA 27/3 
group revealed a higher incidence of joint symptoms, but not rash, 
among RA 27/3 rubella-susceptible vaccinees (P < 0.005). The number of 
reactions in the RA 27/3 group was on the other hand significantly 
lower than in the seronegative HPV-77 DE-5 group (P < 0.001). 
Table IV. Incidence of rash and joint symptoms in seronegative and 
immune women after rubella vaccination. 
Vaccinees Side-effect Cendehi 11 HPV-77 DE 5 RA 27/3 
No % No % No % 
Seronegati ve Rash 19/195 10 53/191 28 17/125 14 
Joint symptoms 14/195 7 80/191 42 22/125 18 
Immune 
Rash 3/102 3 5/99 5 3/102 3 
Joint symptoms 3/102 3 7/99 7 2/102 2 
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Sero log ica l  r e sponse  i n  bab ies  o f  vacc ina ted  mothe r s  
S ix ty - th r ee  bab ies  o f  rube l l a - suscep t ib l e  wom en  vacc ina ted  pos tpa r tum 
were  t e s t ed  a t  the  age  o f  two  t o  e igh t  mon ths  f o r  the  p resence  o f  HI  
an t ibod ie s  (pape r  I ) .  None  o f  t he  ch i ld ren  demons t ra t ed  an  an t ibody  
re sponse ,  i nd ica t ing  tha t  no  immuniza t ion  th rough  t r ansmiss ion  o f  vac ­
c ine  v i rus  had  occu r red .  M any  poss ib i l i t i e s  o f  exposure  e x i s t ed  s ince  
two- th i rds  o f  t he  bab ies  had  been  b reas t - f ed  fo r  a t  l eas t  th ree  months .  
In f luence  o f  an t i - D  immunoglobu l in  and  b lood  t r ans fus ion  
on  t he  se ro log ica l  r e sponse  t o  vacc ina t ion  
To  eva lu a te  i f  b lood  t r ansfus ion  and  ad min i s t r a t ion  o f  an t i -D  immunog lo ­
bu l in  cou ld  in f luence  the  se ro log ica l  r e sponse  t o  rube l l a  vacc ina t ion  
659  obs te t r i c  r epor t s  f rom rube l l a -vacc in a ted  women  we re  examined .  In  
add i t ion  to  the  ma te r i a l  p resen ted  in  pape r  I I  ano the r  fou r  women  w ho  
had  r ece i ved  b lood  t r an s fus ion  dur ing  de l ive ry  were  inc l uded .  
Twe lve  w omen  had  r ec e ived  one  o r  more  un i t s  o f  b lood  i n  connec t ion  wi th  
the  de l ive ry  and  58  women  had  r ece ived  an t i - D  immunog lobu l in .  Th e  s e ro ­
conver s ion  r a t e s  were  97% fo r  the  con t ro l s ,  i . e .  the  589  women  w ho  had  
no t  r ece iv ed  t r ans fus ion  o r  an t i - D  p rophy lax i s ,  and  100% fo r  the  an t i -
D g roup .  In  t he  t r ans fus ion  g roup  on ly  s i x  ou t  o f  twe lve  (50%)  r e spon­
ded  t o  vacc in a t ion  wi th  se roconver s ion .  Th i s  d i f f e rence  was  s t a t i s t i ­
ca l ly  s ign i f i cant  (P  <  0 .001) .  
The  m ean  t i t e r s  a f t e r  vacc ina t io n  in  women  sho wing  s e roconver s ion  va ­
r i ed  be tween  34  and  38  and  no  s ign i f i can t  d i f f e rence  be tween  th e  
g roups  cou ld  be  de tec ted .  In  two  o f  t he  wom en  i n  the  t r an s fus ion  g roup  
HI  an t ibod i es  were  found  in  b lood  samples  o b ta ined  a f t e r  the  t r a ns fu ­
s ion  bu t  be fo re  vacc ina t ion .  In  bo th  c ases  no  HI  an t ibod ies  were  de ­
mons t rab le  e igh t  weeks  a f t e r  vacc ina t ion ,  i nd ica t i ng  th a t  the  H I  t i ­
t e r s  be fo re  immuniza t ion  r e f l ec t ed  pass ive ly  t r ans fe r red  an t ibod ie s .  
Eva lua t ion  o f  a  ne w t e s t ,  hemolys i s - in -ge l ,  fo r  de te rmina t ion  o f  an t i ­
bod ies  t o  rube l l a  
The  hemol ys i s - in -ge l  t echn ique  i s  based  on  the  p r inc ip le s  o f  t he  s ing -
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le radial immunodiffusion method of Mancini et al (1965). In the HIG 
test the antigen is bound to erythrocytes incorporated in agarose g el. 
Specific antibodies will lyse the erythrocytes in the presence of comp­
lement. The te chnique could be expected to be s ensitive and simple to 
perform and thus well suited for both determination of immunity and 
diagnosis of rubella infection. The HI test, generally used, is rather 
simple to perform, but requires titration of sera and absorption to re­
move n onspecific inhibitors and eryt hrocyte agglutinins. 
In the present study a HIG technique suitable for demonstration of ru­
bella antibodies was develope d (paper V). The r elationship between the 
antibody concentration and the size of the hemolytic zone wa s determi­
ned and the sensitivity of this technique for detection of differences 
in antibody concentrations was evaluate d (paper VI). The r esults ob­
tained with the HIG techni que were c orrelated to results of HI and N T 
tests. 
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SERUM DILUT ION 
Fig 1. Regression li nes for five different serum sam ples tested in two­
fold dilutions. The me an diameter and the standard deviation for 6 re^ 
plicates are indicated. The slope value (k) of the regression l ine and 
the hemagglutination-inhibition (HI) titer for each serum sam ple are 
given in the figure. (From Fi g 2 paper VI). 
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Relationship between anti body concentration and siz e of zone of hemo­
lysis. A li near relationship was found between th e diameter of the zone 
of hemolysis and the log antibody concentration after a diffusion time 
of 24 and 48 hours. Five sera with different HI titers were tested in 
twofold dilutions and the regression lines were calculated from the re­
sults of 6 replicates per serum d ilution (Fig 1). As shown i n the figu­
re, the regression lines are almost parallel and a good c orrelation 
between the HI antibody titer and the HIG diameter was fou nd. According 
to these regression lines, twofold and fo urfold titer rises should be 
possible to detect. The sensitivity of HIG f or detecting differences in 
rubella antibody concentrations was f urther evaluated. Twenty-five pai­
red sera with a twofold difference in antibody concentration were tes­
ted in triplicate. In addition 78 paired samples with a fourfold diffe­
rence were te sted as a single specimen and these paired samples were 
also assayed i n HI. All tests were performed w ith coded samples. It 
could be sho wn (Tab le V) that twofold and fo urfold titer differences 
could be de tected with high accuracy in the HIG te st. When th e 78 pai­
red samples were assayed i n HI a tendency towards h igher titer increa­
ses than tested was observed ( Table V). This finding may be r elated to 
the use o f an automa tic diluter in the test. 
Statistical analysis of one of the regression lines showed th at a dif­
ference in diameter of 0.62 mm b etween two serum sa mples after a diffu­
sion time of 24 hours gave a p robability of 0.95 for a p ositive diffe­
rence in antibody concentration. The p robability level for a differen­
ce o f 0.82 mm was found to be 0.99. This indicates that all differen­
ces i n diameter obtained for fourfold differences in antibody concent­
ration and a ll except one for twofold differences may be cons idered 
significant (Table V). When t ested by H I, on th e other hand, 2 of the 
78 paired samples gave no titer difference and 10 of these only a two­
fold increase in titer, a difference which is usually not considered 
significant. 
HIG i n comparison w ith HI and N T. A good co rrelation was found between 
HI and HI G wh en 137 serum samp les were tested. None of 22 sera with HI 
titers less than 20 gave a hemolytic zone diameter > 6 mm and on ly one 
serum wa s found to be p ositive in HI but negative in HIG. In addition, 
93 serum samp les w ith low (HI 20-40) or no ant ibody content as determi­
nated by HI were tested by HIG as w ell as NT. In 33 of these samples 
antibodies were demonstrable by all three methods. Of 60 sera with HI 
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t i t e r s  o f  10  o r  l e s s ,  57  were  a l so  nega t ive  in  HIG a nd  58  in  NT.  Two o f  
the  HI  nega t ive  se ra  con ta ined  an t ib od ies  which  were  demons t rab le  by  
bo th  HIG a nd  NT.  F ina l ly ,  one  se rum wa s  pos i t ive  in  HIG,  had  an  HI  t i ­
t e r  o f  10  and  wa s  nega t ive  in  NT.  
Acu te  and  conv a lescen t -phase  se r a  f rom 55  c l in i ca l  cases  o f  rube l l a  we­
r e  t e s t ed  in  HIG a nd  HI .  Se roconver s ions  were  demons t ra t ed  by  t h e  H I  
me thod  i n  53  cases  and  a l l  these  pa i r ed  samples  a l so  changed  f rom nega­
t ive  to  pos i t ive  r eac t ion  in  HIG.  In  two  pa t i en t s  no  t i t e r  inc rease s  
cou ld  be  sho wn by  e i the r  HIG o r  HI .  However ,  t he  acu te -phase  se ra  were  
ob ta ined  l a t e  a f t e r  the  onse t  o f  r a sh  and  s ign i f i can t  t i t e r  r i s es  were  
shown in  complemen t - f ixa t ion  t e s t s .  
Twen t y  o f  t he  acu te -phase  se r a  con ta ined  H I  an t ibod ies  which  cou ld  no t  
be  demons t ra t ed  by  t h e  HIG t e s t .  Imm unog lobu l in  s epa ra t ion  pe r fo rmed  by  
suc rose  dens i ty  g rad ien t  cen t r i fuga t ion  revea led  tha t  the  f r a c t ions  
con ta i n ing  an t ibod ie s  o f  t he  immunoglobu l in  M ( IgM)  c l a ss  d id  no t  g ive  
hemolys i s  i n  the  HIG t e s t  a l though  an t ib od ies  cou ld  be  demons t ra t ed  in  
these  f r ac t ions  by  th e  HI  me thod .  Ev en  wh en  a  d i f fus ion  t ime  o f  48  
hours  was  used  no  IgM an t ibod ies  cou ld  be  shown .  Thus ,  a  r e l a t ive  in ­
ab i l i t y  o f  t he  HIG t e s t ,  pe r fo rmed  a ccord ing  to  the  p resen t ly  adop ted  
p rocedure ,  t o  de t ec t  rube l l a  an t ibod ies  o f  t he  IgM c l a s s  was  fo und .  
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DISCUSSION 
Comparison betw een the vaccines 
The aim of rubella vaccination is to prevent congenital rubella by cre­
ating an immunity as c lose as p ossible to that induced by natural infec­
tion. Reinfection probably plays an imp ortant role for the maintenance 
of the immunity f ollowing natural infection (Horstmann 1971) and usua l­
ly serves as a booster, with the development o f a q ualitatively and 
quantitatively better immunity. However, cases have been rep orted in 
which re infection has been associated with clinical symptoms (Stranne-
gård et al 1970, Forrest et al 1972, W ilkins et al 1972) and poss ible 
transmission to the fetus (Northrop et al 1972, E ilard and Strannegård 
1974), suggesting that viremia has occ urred. Even.though re infection 
with viremia may be a rare event, the high rate of reinfection seen i n 
vaccinees shortly after immunization causes concern since the duration 
of vaccine-induced immunity i s unknown. The susceptibil ity to reinfec­
tion is related to low a ntibody levels and d ifferences in immunologic 
properties between the vaccines have been suggested (Plotkin et al 
1973). The pre sent study offered an o pportunity to compare the three 
commonly used vaccines in the same t rial regarding immunogenicity, ad­
verse reactions and subse quent immunity t o reinfection. 
Rubella vaccination of newly d elivered women induced an HI antibody 
response in 91 to 96% of the vaccinees w ithout any s ignificant diffe­
rences between the vaccine strains used. HI antibody titers after vac­
cination are in general four to eightfold lower than those seen a fter 
natural infection. In comparative s tudies between the Cendehill and the 
RA 27/3 vaccines higher HI antibody titers have been sho wn af ter immu­
nization with the RA 27/3-strain (Dudgeon et al 1969, Fogel et al 1971, 
Tobin 1971). The C endehill vaccine has bee n re ported to give lower HI 
ti ters than the HPV-77 DE -5 vaccine (Dudgeon et al 1969) but in a stu­
dy by Isacson et al (1971) no c ertain differences were found. However, 
the present study revealed statistically significant differences in HI 
antibody titers between a ll three vaccines, confirming that the RA 27/3 
strain is more immunogenic than the HPV-77 DE -5 va ccine, which i s in 
turn more e ffective than the Cendehill strain. 
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T h e  d i f f e r e nc e s  n o t e d  i n  m e an  t i t e r s  a r e  i m po r t a n t  s i n c e  a  s l i g h t  d e c ­
l i n e  i n  a n t i b o dy  t i t e r s  i s  u s u a l l y  n o t e d  i n  f o l l o w - u p  s tu d i e s  t w o  t o  
s e v e n  y e a r s  a f t e r  v a cc i n a t i o n  ( L i e b ha b e r  e t  a l  1 9 7 2 ,  F a r q uh a r  1 9 7 3 ,  
S ch i f f  e t  a l  1 9 7 4 ,  H i l l e m a n  1 9 7 5 )  a s  w e l l  a s  a f t e r  n a t u r a l  i n f ec t i o n .  
D a v i s  e t  a l  ( 1 9 7 1 )  r e po r t e d  t h a t  l e s s  a n t i g e n i c  v a c c i n e  s t r a i n s  s h o w e d  
t h e  g re a t e s t  l o s s  o f  d e f i n i t e  l e v e l s  o f  H I  a n t ib o d i e s  a f t e r  o n e  t o  
t h r ee  y e a r s .  I n  t h e  p r e s e n t  s t u d y  t h e  m e an  t i t e r s  w e r e  w e l l  m a i n t a i n e d  
i n  t h e  t h r ee  g r o u p s  d u r i n g  t h e  f o l l o w - u p  p e r i o d .  H o w e v e r ,  t h r e e  w o m e n  
i n  t h e  C e n d e h i l l  g r o u p  h a d  H I  t i t e r s  b e l o w  1 0  a f t e r  t w o  y e a r s  a n d  
S c h i f f  e t  a l  ( 1 9 7 4 )  h a v e  r e p o r t e d  t h a t  3 . 9 %  o f  C e nd e h i l l -v a c c i na t e d  
c h i l d r e n  h a d  n o  d e t ec t a b l e  a n t i bo d i e s  4  1 / 2  y ea r  a f t e r  i m m u n i z a t i o n .  
T h e  c o m p a r i s o n  b e t w e e n  HI  a n d  N T  a n t i b o d y  t i t e r s  p e r f o r m e d  i n  t h e  p r e ­
s en t  s t ud y  s u g g e s t ed  t ha t  t h e  m ax i m u m  l e v e l  o f  NT  a n t i bo d i e s  a p p e a r e d  
l a t e r  t h a n  t h a t  o f  H I  a n t i bo d i e s .  T h i s  o b s e r v a t i on  i s  i n  a c c o r d a n c e  
w i t h  t h e  f i n d i n g s  o f  L e e r h 0 y  ( 1 9 5 8 b )  i n  n a t u r a l l y  i n f e c t e d  i n d i v i d u a l s .  
T h e  b e t t e r  n e u t r a l i z i ng  c a p ac i t y  d e m o n s t r a t e d  a f t e r  t w o  y e a r s  m a y  b e  
e x p l a i n e d  b y  d i f f e r e n c es  i n  a v i d i t y  o f  a n t i b o d i e s  p r o d u c e d  e a r l y  a n d  
l a t e  a f t e r  v a c c i n a t i on .  T h e  r i s e  i n  NT  a n t i b o d y  t i t e r s  s e e n  a f t e r  t w o  
y ea r s  c o u l d  n o t  b e  d u e  t o  a  b o o s t e r  r e s p o n s e  t o  n a tu r a l  i n f e c t i o n  s i n ­
c e  n o  s i m u l t a n e o u s  r i s e  i n  HI  a n t i b o d y  t i t e r s  w a s  d e m o ns t r a t e d .  
V a c c i n a t i o n  w i t h  t h e  R A  2 7 / 3  a n d  H P V - 77  D E- 5  s t r a i n s  i n d u c e d  a  n e u t r a ­
l i z in g  a n t i b o dy  r e s po n s e  w h i c h  w a s  s u pe r i o r  t o  t h a t  i n d u c e d  b y  t he  C e n ­
d e h i l l  v a c c i n e .  A t  e i g h t  w e e k s  p o s t i m m u n i z a t i o n  RA  2 7 /3  v a c c i n e e s  a l s o  
d e m o n s t r a t e d  a  b e t t e r  r e s p on s e  c o m p a r e d  t o  t h e  H PV - 7 7  D E - 5  g r o u p .  I n  a  
c o m p a r i s o n  b e t w e e n  t h e  C e n d e h i l l  a n d  t he  R A  2 7 /3  s t r a i n  F o g e l  e t  a l  
( 1 9 7 1 )  r e p o r t e d  s im i l a r  d i f f e r en c e s  s i x  t o  e ig h t  w e e k s  a f t e r  v a c c i n a ­
t i o n  b u t  w h e n  s o me  o f  t h e  v a c c i n e e s  w e r e  r e t e s t e d  a f t e r  s e v e n  m o n t h s  
n o  d i f f e r e n c e s  c o u l d  b e  d e m o n s t r a t e d .  C a r l s s o n  e t  a l  ( 1 9 7 4 )  f o u n d  N T  
a n t i b o d i e s  i n  9 5 %  o f  a du l t  w o me n  1 2  w e e k s  a f t e r  v a c c i n a t i o n  w i t h  t h e  
C en d e h i l l ,  H P V - 7 7  D E - 5  a n d  R A  2 7 / 3  v a c c i n e s .  No  d i f f e r e n c es  w e r e  f o u n d  
b e t w e e n  t h e  v a c c i n e  g r o u p s  b u t  s e r a  w e r e  o n l y  t e s t e d  u n d i l u t e d .  
T h e  N T  a n t i b o d y  t i t e r s  w e  h a v e  s e e n  a f t e r  v a c c i na t i o n  w e r e  i n  g e n e r a l  
l o w .  T h e  l o w e s t  m e d i a n  t i t e r s  w e r e  s e e n  i n  t h e  C e n d e h i l l  g r o u p  a t  b o t h  
e i g h t  w e e k s  a n d  t w o  y e a r s  p o s t v ac c i n a t i o n  w h i l e  n o  d i f f e r e nc e s  w e r e  
f o u n d  b e t w e e n  t he  o t h e r  t w o  g r o up s .  O t h e r  c o m pa r a t i v e  s tu d i e s  b e t w e e n  
t h e  C e n d e h i l l  a n d  RA  2 7 / 3  v a c c i n e s  h a v e  a l s o  d e m o ns t r a t e d  l o w e r  NT  a n ­
t i b od y  t i t e r s  a f t e r  C e n d e h i l l  v a cc i n a t i o n  ( T o b i n  1 9 7 1 ,  P l o t k in  e t  a l  
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1973 ) .  
The  qu an t i t a t i v e ly  be t t e r  HI  an d  N T an t i body  r e sponse  obse rved  i n  R A 
27 / 3  vacc inee s  wa s  f o u n d  t o  co r r e l a t e  w i t h  a  l ower  su scep t i b i l i t y  t o  
i n t r anas a l  ch a l l en ge  tw o  ye a r s  pos t i r n mun iza t i on .  Am o n g  Cendeh i l l  v a cc i ­
nee s  a  s i g n i f i c a n t ly  h ig h e r  r e i n f ec t i on  r a t e  was  o b se r v ed  wh i l e  H PV -77  
DE- 5  vacc inee s  demons t r a t ed  a  susc ep t i b i l i t y  r a t e  i n  be tween  t ha t  o f  
RA 27 /3  and  Cendeh i l l  v acc inee s .  Mos t  cha l l enge  s t ud i e s  have  i nvo lved  
r a the r  sma l l  g roups  an d  ha ve  u sua l l y  no t  i nc lude d  c om pa r i s on  o f  a l l  
t h r ee  vacc ine  s t r a i n s .  Th e  f i nd ing s  o f  t he  p r e se n t  compa ra t i ve  s t udy  
a r e  i n  ag reem en t ,  howeve r ,  w i t h  r e su l t s  o f  t he  o the r  non -compara t i ve  
s t u d i e s .  Thus ,  a  h ig h  r e i n f ec t i on  r a t e  ha s  bee n  obse rved  a m ong  C en d e ­
h i l l  and  HP V -77  D E- 5  vacc inee s  bo th  a f t e r  e xposu re  t o  w i ld  r ube l l a  v i ­
ru s  and  a f t e r  cha l l e n g e  w i t h  i n t r a na sa l l y  admin i s t e r ed  v i ru s  (Wi lk in s  
e t  a l  1969 ,  Chang  e t  a l  1970 ,  H or s tm ann  e t  a l  1970b ,  Dav i s  e t  a l  1971 ) .  
I n  con t r a s t ,  a  l ower  r e i n f ec t i on  r a t e  ha s  been  d e mons t r a t e d  a f t e r  RA 
27 / 3  immu n iz a t i on  (L i ebhabe r  e t  a l  1972 ,  P lo tk in  e t  a l  1973 ) .  I n  ano the r  
c omp a ra t i ve  s t udy  i n  ch i l d r en ,  Og ra  e t  a l  (1 9 7 3)  f ound  t ha t  a  boos t e r  
an t i body  r e sponse  occu r r ed  mos t  o f t e n  among  Cendeh i l l  and  HP V -77  DE- 5  
vacc i n ee s  a f t e r  cha l l e nge .  Ch i l d r en  im mu n ized  w i th  R A 27 /3  b y  t h e  sub ­
cu t aneous  r o u t e  we re  mo re  su s cep t i b le  t o  r e in f e c t i on  t han  t hose  who  r e ­
ce ived  t he  v acc i ne s  i n t r a na sa l l y  o r  we re  na tu r a l l y  i m mune .  
The  l ower  r e i n f ec t i on  r a t e  am ong  RA 27 /3  v acc in ee s  i s  a l so  r e l a t ed  t o  
t he  qu a l i t a t i ve ly  be t t e r  imm une  r e sponse  e l i c i t ed  by  t h i s  vacc ine .  Thus ,  
bo th  p r ec ip i t a t i n g  i o t a  an t i b od i e s  and  s e c r e t o ry  I g A  an t i bod i e s  a r e  r e ­
gu la r l y  found  a f t e r  bo th  i n t r anas a l  an d  subcu t aneous  R A 27 /3  immun iza ­
t i o n ,  whe rea s  t he se  an t i b od i e s  a r e  r a r e ly  de t ec t ed  a f t e r  va c c i na t i on  
w i t h  t he  C endeh i l l  an d  H P V-7 7  DE- 5  vacc ine s  (Le  Bouv i e r  an d  P lo tk in  
1971 ,  Og ra  e t  a l  197 1 ) .  T he  p r e sence  o f  i o t a  an t i b od i e s  ha s  be e n  c l a i ­
med  t o  co r r e l a t e  d i r ec t l y  w i t h  t he  appea rence  o f  r e s i s t a nc e  t o  r e in f ec ­
t i o n  (H o r s tmann  e t  a l  1970b ,  L i ebhabe r  e t  a l  1972 ) ,  an d  s e c r e to ry  I g A  
an t i b od i e s  a r e  obv ious ly  impor t an t  f o r  p ro t e c t i o n  aga in s t  v i r a l  i n f ec ­
t i o ns  o f  r e sp i r a to ry  mucosa .  
A no th e r  q ua l i t a t i ve  d i f f e r en ce  be twee n  t he  vacc ine s  i s  t he i r  a b i l i t y  t o  
i nduce  a  bo o s t e r  r e sponse  by  r evac c ina t i on .  The  RA 27 /3  r ube l l a  v acc in e  
wh ich  can  b e  admin i s t e r ed  i n t r anas a l ly ,  h a s  been  succ e s s fu l l y  u sed  t o  
boos t  vacc ine - i nduced  im m u n i ty  (P l o tk i n  e t  a l  19 73 ,  p ap e r  IV )  wh i l e  t h e  
u se  o f  subcu t aneous ly  adm i n i s t e r ed  r ube l l a  vacc ine s  ha s  me t  w i th  on ly  
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par t i a l  success  (Wyl l  e t  a l  1971 ,  Chang  e t  a l  1973) .  I t  i s  r easonab le  
t o  assume  t ha t  t h i s  type  o f  vacc ina t ion  may  be  a  va luab le  supp lemen t  
t o  boos t  waning  immuni ty  i n  adu l t  women  w ho  have  been  va cc ina ted  dur ing  
ch i ldhood  o r  ado lescence .  
As  a  ru l e ,  a  l i nea r  r e la t i onsh ip  ex i s t s  be tween  t he  immunogen ic i ty  and  
the  r eac toge n ic i ty  o f  a  vacc ine .  However ,  t he  RA 27 /3  s t r a in  seems  t o  
be  an  excep t ion  to  th i s  ru l e .  In  t he  p resen t  s tudy  suscep t ib l e  R A 27 /3  
vacc inees  expe r i enced  jo in t  symptoms  and  r a sh  s ign i f i c an t ly  l e ss  o f t en  
than  HPV-77  DE -5  vacc in ees .  In  the  l a t t e r  g roup  t he  s ide -e f fec t s  indu­
ced  by  vacc ina t ion  were  a l so  mo re  s ev e re  and  o f  l onger  du ra t ion  than  
in  the  o the r  two  g roups .  In  a  f ew w omen  vacc ina ted  wi th  the  HPV-77  DE-5  
vacc ine  the  jo in t  symptoms  pe rs i s t ed  fo r  up  t o  two  mo nths  and  one  wom an  
s t i l l  has  r ecu r r en t  a r th r i t i s  a f t e r  th ree  yea r s .  Lerman  e t  a l  (1971)  
r epor t ed  the  same  sym ptom in  one  wo man  du r ing  a t  l eas t  one  yea r  fo l lo ­
wing  HPV-7 7  DE- 5  immuniza t ion .  In te rmi t t en t  a r t h r i t i s  has  a l so  been  d e ­
sc r ibed  in  ch i ld ren  fo l lowing  immuniza t ion  wi th  the  H PV-7 7  DK-12  vac ­
c ine  (Thompson  e t  a l  1973) .  O the rwise ,  adve r se  r eac t ions  a r e  r a re  in  
ch i ld ren  and  there  seems  t o  be  l i t t l e  d i f f e rences  in  inc idence  and  s e ­
ve r i ty  be tween  t he  th ree  ava i l ab le  vacc ine  s t r a in s  (Andzhapar idze  e t  a l  
1970 ,  Wal l ace  and  I sacsson  1972) .  The  Cendeh i l l  vacc ine  has  been  a s s o ­
c i a t ed  wi th  f ew and  mi ld  s ide -e f fec t s  in  adu l t  w omen  (Du dgeon  e t  a l  
1969 ,  Foge l  e t  a l  1971 ,  Tob in  1971)  and  i n  the  p resen t  s tudy  jo in t  
symptoms  occur red  s ig n i f i can t ly  l e ss  f r equen t ly  compared  t o  in  RA 27 /3  
and  HPV-77  DE- 5  va cc inees .  
A n ew Japanese  v acc ine ,  To-366 ,  has  r ecen t ly  been  used  in  a  compara t ive  
t r i a l  (Bes t  e t  a l  1974) .  The  To -366  s t r a in  was  found  t o  induce  an  HI  
an t ibody  re sponse  comparab le  t o  tha t  obse rved  wi th  t he  RA 27 /3  and  
HPV- /7  DE- 5  s t r a in s  wi th  a  low inc idenc e  o f  adve r se  r eac t i ons .  The  J a ­
panese  vacc ine  may  be  o f  i n t e re s t  fo r  fu r ther  eva lua t ion  s ince ,  i t  has  
been  c l a imed  to  be  l e s s  t e ra togen ic  in  r ab b i t s  than  o the r  rube l l a  v i ­
rus  s t r a ins  (Kon o  e t  a l  1969) .  
Rube l l a  vacc in a t ion  dur ing  the  pos tpa r tum pe r iod  
Vacc ina t ion  dur ing  the  pos tpa r tum pe r iod  i s  as soc ia t ed  wi th  some  p a r t i ­
cu la r  p rob lems .  There  i s  a  sma l l  bu t  de f in i t e  r i sk  o f  concep t ion  wi th in  
two  mo nths  pos tpa r tum (Ba ld win  and  F rees tone  1971 ,  Seve r  1971)  and  thus ,  
con t racept ives  shou ld  be  used  a l so  when  newly  de l iv e red  wom en  a r e  immu­
n ized .  
Al though  t r ansmiss ion  o f  vacc ine  v i rus  to  con tac t s  has  no t  been  p roven  
t o  occur  (D udgeon  e t  a l  1969 ,  Ha l s t ead  and  Diwan  1971 ,  Sco t t  and  Byrne  
1971)  bab ies  t o  vacc ina ted  mothe r s  a r e  p rone  t o  be  exposed  because  o f  
t he  c lose  con tac t  be tween  mothe r  and  c h i ld .  However ,  i n  ag reemen t  w i th  
Boue  e t  a l  (1969)  and  Tob in  (1971)  we  cou ld  no t  demons t ra t e  any  immun i ­
za t i on  o f  t he  bab ies  ind ica t ing  tha t  p robab ly  no  t r an smiss ion  o f  v i rus  
had  occ ur red .  
Admin i s t r a t ion  o f  an t i -D  immunog lobu l in  and  t r an s fus ion  o f  b lood  cou ld  
be  supposed  t o  in f lu ence  the  se ro log ica l  r e sponse  t o  vacc ina t ion .  There  
was  no  ev idence  tha t  an t i -D  immunoglobu l in  i n t e r fe red  wi th  the  e f f ec t i ­
veness  o f  t he  vacc ina t ion  in  accordance  wi th  the  f ind ings  o f  Gr l inbe rge r  
e t  a l  (1972 )  and  Maroni  and  Munz inge r  (1975) .  B lood  t r a ns fus ion ,  on  t he  
o ther  hand ,  r educed  the  se roconver s ion  r a t e  s ign i f i c an t ly  and  i t  i s  
the re fo re  e s sen t i a l  t ha t  the  r esu l t  o f  vacc ina t io n  in  th i s  g roup  o f  wo­
men  i s  con t ro l l ed  a f t e r  e igh t  weeks .  
Abou t  5 -7% o f  vacc inees  f a i l  t o  re spond  to  vacc ina t ion  bu t  a l l  f a i lu res  
a r e  no t  due  t o  b lock ing  o f  vacc ine  v i rus  f rom pa ss ive ly  t r ans fe r red  an ­
t ibod ies .  Inadver t en t  i nac t i va t ion  o f  t he  vacc ine  may  occur  i f  the  manu­
f ac tu r e r s  recommenda t ions  fo r  s to rage  and  r econs t i tu t ion  a re  no t  fo l l o ­
wed .  However ,  t he  vacc ina ted  women  who  f a i l  t o  r e spond ,  be l i eve  them­
se lves  to  be  p ro tec ted  aga ins t  rube l l a  and  ma y  t he re fo re  neg lec t  t o  
seek  med ica l  adv ice  and  examina t ion  on  exposu re .  These  r i sks  cou ld  be  
p reven ted  by  a  rou t ine  con t ro l  o f  t he  r e su l t s  o f  immuni za t ion  a f t e r  
vacc ina t ion  o f  adu l t  women.  
De te rmina t ion  o f  rube l l a  an t ibod ies  by  he molys l s - in -ge l ,  hemagg lu t ina -
t ion - inh ib i t ion  and  neu t ra l i z a t ion  t e s t s .  
Af te r  na tu ra l  rube l l a  in fec t ion  HI  and  NT an t ibod i es  usua l ly  appea r  
wi th in  a  . few days  a f t e r  onse t  o f  r a sh  and  then  pe r s i s t  p robab ly  l i f e ­
long .  The  p resence  o f  NT an t ibo d ies  i s  gene ra l ly  accep ted  a s  a  more  r e ­
l i ab l e  ind ica t ion  o f  immuni ty  than  HI  an t ibod ies .  However ,  t he  NT t e s t  
i s  t ime-consumin g  t o  pe r fo rm and  no t  we l l  su i t ed  fo r  de te rmina t ion  o f  
immuni ty  i n  a  l a rge  sca le .  The  H I  t e s t ,  on  the  o the r  hand ,  i s  r a the r  
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s imple  t o  pe r fo rm bu t  the  p resence  o f  nonspec i f i c  i nh ib i to r s  o f  hemagg­
lu t ina t io n  in  se r a  some t imes  causes  an  unce r t a in ty  abou t  t he  d i agnos t i c  
va lue  o f  low H I  t i t e r s .  
In  the  p resen t  s tudy  ano the r  t e s t ,  HIG,  was  i n t ro duced  fo r  the  demons t ­
r a t ion  o f  an t ibod ies .  The  H IG t echn ique  was  found  to  be  s ens i t ive  and  
t o  g ive  r ep roduc ib le  r e su l t s  in  ag reemen t  wi th  the  f ind ings  o f  Russe l  
e t  a l  (1975 )  and  Skau g  e t  a l  (1975) .  Th e  t e s t  i s  in  con t ra s t  t o  the  H I  
me thod  independen t  w i th in  ce r t a in  l imi t s  o f  t he  concen t ra t ion  o f  an t i ­
gen  (pape r  V) .  However ,  t he  cho ice  o f  e ry th rocy tes  see ms  t o  be  impor ­
t an t .  P igeon  RBC we re  more  s e ns i t i ve  than  sheep  e ry th rocytes  and  a l so  
gave  f ewer  nonspec i f i c  hemoly t i c  r eac t ions .  Al though  nonspec i f i c  l y s i s  
i s  a  r a the r  r a re  phe nomenon ,  when  p igeon  RBC i s  used ,  i t  seems  t o  ne ­
cess i t a t e  the  use  o f  con t r o l  p la te s ,  i . e .  p l a t e s  wi th  uncoa ted  e r y th ro ­
cy t es .  Ins t ead  o f  p igeon  c e l l s  ch icken  RBC can  be  used  in  the  t es t  a s  
shown by  Ska ug  e t  a l  (1975)  who  ob ta ined  r e su l t s  wi th  a  good  c o r re la ­
t ion  to  the  r e su l t s  o f  t he  rube l l a  H I  t e s t .  
In  t he  s ing le  r ad ia l  immunod i f fus ion  me t hod  o f  Manc in i  e t  a l  (1965)  a  
l i n ear  r e l a t ionsh i p  i s  ob ta ined  be tween  th e  a rea  and  the  an t ibody  con­
cen t ra t ion  when  equ i l ib r ium i s  reached ,  i . e .  when  a n t ibod ie s  a re  no  
longer  ava i l ab le  t o  r eac t  wi th  the  an t igen  in  the  ge l .  For  a n t ibod ie s  
o f  t he  immunog lobu l in  G c l a s s  t h i s  wi l l  no t  be  ach ieved  wi th in  a  d i f ­
fus io n  t ime  o f  f ive  to  s ix  days .  Ho wever ,  be fo re  t h i s  t ime  a  l i near  r e ­
l a t ionsh ip  ex i s t s  be tween  t he  d iamete r  o f  t he  zone  and  the  log  o f  t he  
an t ibody  concen t ra t ion  (Fahey  e t  a l  1965) .  Th i s  was  a l so  found  t o  be  
va l id  fo r  the  HIG t e s t ,  where  t he  d i f fus ion  t ime  usua l ly  cou ld  no t  be  
ex tended  beyond  48  hours  due  t o  the  in s t ab i l i ty  o f  t he  e ry th rocy tes .  
I t  was  sh own tha t  fou r fo ld  and  even  lower  t i t e r  inc reases  cou ld  be  de ­
t ec ted  wi th  a  h igh  degree  o f  accuracy  a f t e r  a  d i f fus ion  t ime  o f  24  
hours .  An  i n c rease  o f  t h i s  t ime  up  t o  48  hours  gave  h ig he r  s lope  va lues  
and  thus  l a rge r  d i f f e rences  in  d i amete r .  However ,  t he  s t anda rd  dev ia ­
t ion  inc reased  and  the  accuracy  o f  t he  t e s t  i s  p robab ly  no t  f avoured  
by  a  d i f fus ion  t ime  longer  than  24  hours .  
Se roconver s ions  a f t e r  na tu ra l  i n f ec t ions  were  ea s i ly  de tec ted  by  HI G 
seven  to  t en  days  a f t e r  onse t  o f  r a sh .  The  on ly  l imi t a t ion  h i the r to  
obse rved  seems  t o  be  i t s  inab i l i t y  to  de t ec t  rube l l a - spec i f i c  IgM an ­
t ibod ies .  Th i s  has  a l so  been  sho wn t o  be  v a l i d  fo r  in f luenza  (Russe l  
e t  a l  1975)  bu t  i s  no t  ye t  s a t i s f ac to r i ly  exp lo red .  Because  o f  t he  in -
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ab i l i t y  t o  de t ec t  Ig M an t i bod i e s  by  H IG t he  HI  t e s t  m a y  be  p r e f e r r ed  
f o r  t h e  demons t r a t i on  o f  ve ry  e a r l y  t i t e r  r i s e s  i . e .  t h r ee  t o  fou r  da ys  
a f t e r  onse t  o f  r a sh .  Th e  s a me  i s  va l i d  whe n  t he  e a r l y  r e sponse  t o  vacc i ­
na t i o n  i s  s t ud i ed .  I n  t he  p r e sen t  s t udy  3  ou t  o f  55  w om en  had  no  demo ns ­
t r ab l e  an t i b od i e s  acco rd ing  t o  H IG bu t  t he i r  s e r a  we re  a l l  pos i t i v e  i n  
HI  e i g h t  weeks  a f t e r  va c c ina t i on .  
A  g oo d  co r r e l a t i o n  was  f o u n d  be t wee n  t he  r e su l t s  o f  H I G and  N T w hen  s e ­
r a  w i th  l o w  o r  no  HI  an t i body  t i t e r s  were  t e s t e d .  Th u s ,  s i nc e  t he  H IG 
t e s t  i s  r ap id ,  s imp le  t o  pe r fo rm  an  una f f e c t e d  by  nonsp ec i f i c  i nh ib i ­
t o r s  i t  i s  we l l  s u i t ed  f o r  s c r een ing  o f  im mu n i ty  i n  a  l a rg e  s c a l e .  I t  
m ay  be  conc luded  t h a t  t he  H IG t e s t  s eem s  t o  be  a  good  a l t e rna t i v e  t o  
H I  f o r  de t e rmina t i on  o f  r u be l l a  immu n i t y  a s  w e l l  a s  f o r  t he  s e ro log i c a l  
d i agno s i s  o f  r ube l l a .  
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SUMMARY AND CONCLUDING REMARKS 
Three rubella vaccines (Cendehill, HPV-77 DE-5 and RA 27/3) were used 
for immunization of adult women postpartum. Serological responses and 
adverse reactions were studied and the three vaccines were compared. 
The susceptibility to intranasally administered challenge virus two 
years after vaccination were investigated. 
Differences in serological response and adverse reactions were obser­
ved. The best HI and NT antibody response, at eight weeks postvaccina-
tion, were seen after immunization with RA 27/3. The immunity induced 
by this vaccine gave the best protection against intranasal challenge, 
reinfection, two years later. The HPV-77 DE-5 vaccine gave the largest 
number of side-effects, which in addition were more severe and of a 
longer duration than those observed after vaccination with the two 
other strains. In Cendehill vaccinees few and mild side-effects were 
noticed but also the lowest HI and NT antibody response. After two 
years a significantly greater susceptibility to intranasal challenge 
was found in this group. The differences in immunogenicity between the 
vaccines are particularly important to consider since the duration of 
vaccine-induced immunity is unknown. 
Previous administration of anti-D immunoglobulin had no effect on the 
serological response whereas a previous blood transfusion significant­
ly decreased the seroconversion rate. It, thus, seems particularly im­
portant to control the result of the vaccination in the latter group 
of vaccinees. In the study we could not demonstrate any serological 
signs of a possible transmission of vaccine virus to the babies of vac­
cinated mothers. 
A new method, the HIG technique (hemolysis-in-gel) was found to be well 
suited for determination of immunity with a good correlation to results 
of HI and NT tests. The technique has the advantage of being indepen­
dent of nonspecific inhibitors and does not require titration of sera. 
Seroconversions and fourfold and even twofold differences in antibody 
concentrations were detected by HIG with a high degree of accuracy. 
Thus, the HIG test may as well be used for the diagnosis of rubella 
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i n fec t ion .  One  l imi ta t ion  o f  the  t e s t  h i ther to  obse rve d  i s  i t s  inab i l i ­
ty  to  de tec t  rube l l a - spec i f i c  IgM an t ibod ies ,  a t  l eas t  wi th  the  p resen t ­
ly  adop ted  p rocedure .  
32 
ACKNOWLEDGEMENTS 
My s incere thanks ar e due to: 
Erik Lycke, head o f the Department of Virology, for the guidance and 
the invaluable discussions throughout the investigation. 
Per Hedlund, head o f the Department of Infectious Diseases, for a ne­
ver failing interest and support of the study. 
Örjan Strannegård, Carl-Erik Hedström and Lars Forssman for a stimu­
lating collaboration. 
Agnete Lundmark, Ingrid Bergqvist and Mona Eriksson for skilful tech­
nical assistance during various parts of the study. 
Runa-Lisa Dannberg for skilful and pat ient typing of the various ver­
sions of these papers. 
Gaby Mathiasson and Da n Groth for excellent help with the i l lustra­
tions . 
Anders Odën for help with statistical analyses. 
Inger Olsson, who ha s kept all data from the patients in a perfect 
order. 
All other members o f the Departments of Virology and I nfectious Disea­
ses f or their support. 
The investigation was supported by the Axel Lennart Larsson, the Wil­
helm and Martina Lundgren and the Hjördis Lindegren Foundations, Uni­
versity of Göteborg. 
The vaccines were kindly supplied by Smith Kline and Fren ch (Cendehill, 
Cendevax), Merck Sharp and D ohme (HPV-77 DE- 5, Meruvax) and Burr oughs 
Wellcome (RA 27/3, Almevax). 
33 
R E F E R E N C E S  
A n d z h a p a r i d z e ,  O . G . ,  D e s y a t s k o v a ,  R . G . ,  C h e r v o n s k i ,  G . I .  a n d  P r y a n i c h -
n i k o v a ,  L . V . :  I m m u n o g e n i c i t y  a n d  r e a c t o g e n i c i t y  o f  l i v e  a t t e n u a t e d  r u ­
b e l l a  v i r u s  v a c c i n e s .  A m  J  E p i d e m i o l  9 1 :  5 2 7 - 5 3 0 ,  1 9 7 0 .  
B a l d w i n ,  J . A . ' a n d  F r e e s t o n e ,  D . S . : R i s k  o f  e a r l y  p o s t - p a r t u m  p r e g n a n c y  
i n  c o n t e x t  o f  p o s t - p a r t u m  v a c c i n a t i o n  a g a i n s t  r u b e l l a .  L a n c e t  i i :  3 6 6 -
3 6 7 ,  1 9 7 1 .  
B a n a t v a l a ,  J . E . :  M a t e r n a l  r u b e l l a  a n d  i t s  v i r o l o g i c a l  d i a g n o s i s .  P o s t ­
g r a d  M e d  J ,  S u p p l .  4 8 :  1 1 - 1 7 ,  1 9 7 2 .  
B e a l e ,  A . J . :  M e a s l e s  a n d  r u b e l l a  v a c c i n a t i o n .  A c t a  M e d  S c a n d ,  S u p p l .  
5 7 6 :  3 9 - 4 4 ,  1 9 7 5 .  
B e s t ,  J . M . ,  B a n a t v a l a ,  J . E . ,  A l m e i d a ,  J . D .  a n d  W a t e r s o n ,  A . P . :  M o r p h o ­
l o g i c a l  c h a r a c t e r i s e  c s  o f  r u b e l l a  v i r u s .  L a n c e t  i  i  :  2 3 7 - 2 3 9 ,  1 9 6 7 .  
B e s t ,  J . M . ,  B a n a t v a l a ,  J . E .  a n d  B o w e n ,  J . M . :  N e w  J a p a n e s e  r u b e l l a  v a c ­
c i n e :  C o m p a r a t i v e  t r i a l s .  B r  M e d  J  3 :  2 2 1 - 2 2 4 ,  1 9 7 4 .  
B o u é ,  A . ,  P a p i e r n i c k - B e r k h a u e r  E .  a n d  L é v y - T h i e r r y ,  S . :  A t t e n u a t e d  
r u b e l l a  v i r u s  v a c c i n e  i n  w o m e n .  A m  J  D i s  C h i l d  1 1 8 :  2 3 0 - 2 3 3 ,  1 9 6 9 .  
B u y n a k ,  E . B . ,  H i l l e m a n ,  M . R . ,  W e i b e l ,  R . E .  a n d  S t o k e s ,  J .  J r . :  L i v e  
a t t e n u a t e d  r u b e l l a  v i r u s  v a c c i n e s  p r e p a r e d  i n  d u c k  e m b r y o  c e l l  c u l t u r e .  
J A M A  2 0 4 :  1 9 5 - 2 0 0 ,  1 9 6 8 .  
C a r l s s o n ,  M . G . ,  J o h n s s o n ,  T .  a n d  R e n m a r k e r ,  K . :  R u b e l l a  v a c c i n a t i o n  o f  
h o s p i t a l  s t a f f :  L ä k a r t i d n i n g e n  7 1 :  1 9 5 5 - 1 9 5 8 ,  1 9 7 4 .  
C h a n g ,  T . - W . ,  D e s  R o s i e r s ,  S .  a n d  W e i n s t e i n ,  L . :  C l i n i c a l  a n d  s e r o l o ­
g i c  s t u d i e s  o f  a n  o u t b r e a k  o f  r u b e l l a  i n  a  v a c c i n a t e d  p o p u l a t i o n .  
N  E n g l  J  M e d  2 8 3 :  2 4 6 - 2 4 8 ,  1 9 7 0 .  
C h a n g ,  T . - W . ,  D e s  R o s i e r s ,  S .  a n d  W e i n s t e i n ,  L . :  B o o s t e r  i m m u n i z a t i o n  
a g a i n s t  r u b e l l a  i n  a d u l t  w o m e n .  A r c h  I n t e r n  M e d  1 3 1 :  5 3 0 - 5 3 1 ,  1 9 7 3 .  
C o o p e r ,  L . Z . ,  Z i r i n g ,  P . R . ,  O c k e r s e ,  A . B . ,  F e d u n ,  B . A . ,  K i e l y ,  B .  a n d  
K r u g m a n ,  S . :  R u b e l l a .  C l i n i c a l  m a n i f e s t a t i o n s  a n d  m a n a g e m e n t .  A m  J  
D i s  C h i l d  1 1 8 :  1 8 - 2 9 ,  1 9 6 9 .  
C o o p e r ,  L . Z . :  R u b e l l a  i n  t h e  U S A ,  t h e  p r o b l e m s .  S c a n d  J  I n f e c t  D i s  
S u p p l  6 :  7 - 1 3 ,  1 9 7 2 .  
D a v i s ,  W . J . ,  L a r s o n ,  H . E . ,  S i m s a r i a n ,  J . P . ,  P a r k m a n ,  P . D .  a n d  M e y e r ,  
H . M . J r . :  A  s t u d y  o f  r u b e l l a  i m m u n i t y  a n d  r e s i s t a n c e  t o  i n f e c t i o n .  
J A M A  2 1 5 :  6 0 0 - 6 0 8 ,  1 9 7 1  .  
D u d g e o n ,  J . A . ,  M a r s h a l l ,  W . C .  a n d  P e c k h a m ,  C . S . :  R u b e l l a  v a c c i n e  t r i a l s  
i n  a d u l t s  a n d  c h i l d r e n .  A m  J  D i s  C h i l d  1 1 8 :  2 3 7 - 2 4 2 ,  1 9 6 9 .  
D u d g e o n ,  J . A . :  R e c e n t  a d v a n c e s  i n  t h e  s t u d y  o f  r u b e l l a .  A n n  R e v  S e i  
B a s i s  M e d  6 1 - 8 8 ,  1 9 7 0 .  
34 
Eilard, T. and Strannegård, ö.: Rubella reinfection in pregnancy follo­
wed by tra nsmission to the fetus. J Infect Dis 129: 594-596, 1974. 
Fahey, J.L. and M cKelvey, E. M.: Quantitative determination of serum im­
munoglobulins in antibody agar p lates. J Immunol 94: 84-90, 1965. 
Farquhar, J.D.: Experience with rubella and rub ella immunization in in­
stitutionalized children. J Pediatr 83: 51-56, 1973. 
Feldman, H.A.: Removal by hepar in - Mn Cl o of nonspecific rubella hem­
agglutinin serum i nhibitor. Proc Soc Exp Bi ol Med 127: 570-573, 1968. 
Fleet, W.F., Benz, E.W., Karzon, D.T., Lefkowitz, L.B. and He rrmann, 
K.L.: Fetal consequences of maternal rubella immunization. JAMA 227: 
621-627, 1974. 
Fogel, A., Moshkowitz, A., Rannon, L . and Geric hter, Ch.B.: Comparati­
ve tr ials of RA 27/3 and Cendehil l rubella vaccines i n adult and ad ole­
scent females. Am J Epidemiol 93: 392-398, 1971. 
Forrest, J.M., Menser, M.A., Honeyman, M .C., Stout, M. and . Murphy, 
A.M.: Clinical rubella eleven months a fter vaccination. Lancet i i :  399-
400, 1972. 
Furesz, J., Moreau, P. and Yarosh , W.: A micro t issue culture test for 
the t itration and ne utralization of rubella virus. Can J Mi crobiol 15: 
67-71, 1969. 
Gregg, N.McA.: Congenital cataract fol lowing german measles i n the 
mother. Trans Ophtalmol Soc Aust 3: 35-46, 1941. 
GrLinberger, V., Hinterberger, K. and Hofmann, H.: The e ff icacy of ru­
bella immunization i n combination w ith the administration of anti-D 
gammaglobulin. Wiener K lin Wochenschr. 84: 627-629, 1972. 
Halonen, P.E., Ryan, J.M. and Stewart, J.A.: Rubella hemagglutinin pre­
pared w ith alkaline extraction of virus grown in suspension cu lture of 
BHK 21 cells. Proc Soc Exp Bio l Med 125: 162-167, 1967. 
Halstead, S.B. and Diwan, A.R.: Failure to transmit rubella virus vac­
cine. JAMA 215: 634-636, 1971. 
Hardy, J.B., McCracken, G.H. Jr., Gilkeson, M.R. and Sever, J.L.: Ad­
verse fetal outcome fo llowing maternal rubella after the f irst trimes­
ter of pregnancy. JAMA 207: 2414-2420, 1969. 
Hil leman, M.R.: The new er l ive virus vaccines. Acta M ed S cand Sup pl 
576: 55-64, 1975. 
Horstmann, D.M., Pajot, T.G. and Liebhaber, H.: Epidemiology o f rubel­
la. Am J Dis Child 118: 133-136, 1969. 
Horstmann, D.M., Liebhaber, H. and Koho rn, E .I.: Post-partum vaccina­
tion of rubella-susceptible women. Lancet i  i  :1003-1006, 1970 a. 
Horstmann, D.M., Liebhaber, H., Le Bouv ier, G.L., Rosenberg, D.A. and 
Halstead, S.B.: Rubella: Reinfection of vaccinated and na turally immu­
ne person s exposed i n a epidemic. N En gl J Med 283: 771-778, 1970 b. 
35 
Horstmann, D.M.: Rubella: The chall enge of i ts control. J Infect Dis 
123: 640-654» 1971. 
Huygelen, C. and Pe etermans, J .: Attenuation of rubella virus by serial 
passage i n primary rabbit kidney cell cultures. Arch Ges Virusforsch 
21: 357-365, 1967. 
Isacson, P., Kehrer, A.F., Wilson, H. and Will ia ms, S.: Comparative 
study of l ive, attenuated rubella vaccines d uring the immediate puerpe-
rium. Obstet Gynecol 37: 332-337, 1971. 
Kono, R., Hibi, M., Hayakawa, Y. and I shii , K.: Experimental vertical 
transmission of rubella virus in rabbits. Lancet i :  343-347, 1969. 
Le Bou vier, G.L. and P lotkin, S.A.: Precipit in responses to rubella 
vaccine RA 27/3. J Infect Dis 123: 220-223, 1971. 
Leerh0y, J.: Rubella virus neutralization in heated sera. Acta Path 
Microbiol Scand"73: 275-282, 196 8 a. 
Leerh0y, J.: Development and persis tence of neutralizing antibody in 
human rub ella infection. Acta Path M icrobiol Scand 74: 77-84, 1968 b. 
Lennette, E.H., Woodie, J.D. and Schmidt, N.-J.: A modified indirect 
immunofluorescent s taining technique for the demonstration of rubella 
antibodies in human sera. J Lab Cli n Med 69: 689-695, 1967. 
Lerman, S.J., Nankervis, G.A., Heggie, A.D. and Gold, E.: Immunologic 
response, virus excretion, and jo int reactions with rubella vaccine. 
Ann Int ern Med 74: 67-73, 1971. 
Liebhaber, H.: Measurement o f rubella antibody by hema gglutination in­
hibit ion. II . Characteristics of an improv ed HAI test employing a new 
method fo r the removal of non-immunoglobulin HA inh ibitors from serum. 
J Immunol 104: 826-834, 1970. 
Liebhaber, H., Ingalls, T.H., Le Bouv ier, G.L. and Horstmann, D.M.: 
Vaccination with RA 27/3~rubella vaccine. Am J Dis Child 123: 133-136, 
1972. 
Mancini, G., Carbonara, A.O. and Heremans, J.F.: Immunochemical quan­
t itation of antigens by single radial immunodiffusion. Immunochemistry 
2: 235-254, 1965. 
Maroni, E. and Munzinger, J.: Postpartum rub ella vaccination and a nti-D 
prophylaxis. Br Med J 2: 541-542, 1975. 
Meyer, H. M.Jr., Parkman, P.D. and Panos , T.C.: Attenuated rubella vi­
rus: II . Production of an experimental l ive virus vaccine and cl inical 
tr ial. N En gl J Med 275: 575-580, 1966. 
Meyer, H .M.Jr., Parkman, P.D., Hobbins, T .E. and En nis, F.A.: Clinical 
studies'with experimental l ive rubella virus vaccine (strain HPV-77). 
Am J Dis Child 115: 648-654, 1968. 
Northrop, R.L., Gardner, W. M. and Geittmann, W.F.: Rubella reinfection 
during early pregnancy. Obstet Gynecol 39: 524-526, 1972. 
36 
Ogra, P .L., Kerr-Grant, D., Umana, G., Dzierba, J. and Weintraub, D .: 
Antibody response i n serura and nas opharynx after naturally acquired and 
vaccine-induced infection with rubella virus. N En gl J Med 285: 1333-
1339, 1971. 
Ogra, P.L., Wallace, R.B., Kerr-Grant, D. and Um ana, G.: Vaccine i ndu­
ced rub ella immunity: Response t o reinfection and dev elopment of naso­
pharyngeal antibody. Abstract Pediatric research 7: 377, 1973. 
Parkman, P.D., Buescher, E.L. and Artenstein, M.S.: Recovery o f rubella 
virus from arm y recruits. Proc Soc Exp B iol Med 1 11: 225-230, 1962. 
Parkman, P.D., Mundon, F.K., McCown, J.M. and Bue scher, E .L.: Studies 
of rubella. I I . Neutralization of the virus. J Immunol 93: 608-617, 
1964. 
Parkman, P.D.: Discussion of virology and epidemiology of rubella. 
Am J Dis Child 118: 153-154, 1969. 
Phil l ips, C.A., Maeck, J. van S. , Rogers, W.A. and Sav el, H.: Intraute­
rine rubella infection following immunization with rubella vaccine. 
JAMA 213: 624-625, 1970. 
Plotkin, S.A., Farquhar, J., Katz, M. and I ngalls, T.H.: A ne w atte nua­
ted rubella virus grown i n human f ib roblasts: Evidence f or reduced na­
sopharyngeal excretion. Am J Epidemiol 86: 468-477, 1967. 
Plotkin, S.A., Ingalls, T.H., Farquhar, J.D. and Katz, M.: Intranasal-
ly administered rubella vaccine. Lancet 934-937, 1968. 
Plotkin, S.A., Farquhar, J.D. and Ogra , P.L.: Immunologic properties 
of RA 27/3 rubella virus vaccine. JAMA 225: 585-590, 1973. 
Russell, S.M., McCahon, D. and Beare, A .S.: A sin gle radial hemolysis 
technique for the measurement o f influenza antibody. J Gen V irol 27: 
1-10, 1975. 
Schiff, G.M., Smith, H.D., Dignan, P .St.J., Cincinnati, Ch. B. and 
Sever, J.L.: Rubella: Studies on the natural disease. Am J Dis Child 
110: 366-369, 1965. 
Schiff , G.M., Donath, R. and Rott e, T.: Experimental rubella studies. 
Am J Dis Child 118: 269-274, 1969. 
Schiff, G.M., Rauh, J .L., Linnemann, C.C. Jr., Shea, L ., Rotte, T.C. 
and Tr imble, S.: Rubella vaccinees i n a p ublic school system. A m J Dis 
Child 128: 180-183, 1974. 
Schmidt, N.J. and Lennette, E.H.: Variables of the rubella hemaggluti-
nation-inhibit ion test system and th eir effect on antige n and antibody 
t i ters. Appl M icrobiol 19: 491-504, 1970. 
Scott, H.D. and Byrne, E.B.: Exposure o f susceptible pregnant wo men t o 
rubella vaccinees. JAMA 215: 609-612, 1971. 
Sever, J.L.: Rubella immunization r isk postpartum. JAMA 217: 697, 1971. 
Skaug, K., ßrstavik, I .  and Ulst rup, J.C.: Application of the passive 
haemolysis test for the determination of rubella virus antibodies. 
Acta Path M icrobiol Scand Sect B 83: 367-372, 1975. 
37 
Squire, W.: On ru bella; rubeola sine catarho; Röthein, or German M eas­
les. Transactions of the International Congress o f Medicine 4: 27-31, 
1881. 
Stewart, G.L., Parkman, P.D., Hopps, H.E., Douglas, R.D., Hamilton, J. 
P. and M eyer, H.M.Jr. : Rubella virus hemagglutination-inhibition test. 
N En gl J Me d 276: 554-557, 1967. 
Strannegård, Ö ., Holm, S .E., Hermodsson, S., Norrby, R. and Lycke, E.: 
Case of apparent re infection with rubella. Lancet i :  240-241, 1970. 
Thompson, G.R., Weiss, J.J., Shil l is, J.L. and Br ackett, R.G.: Inter­
mittent arthrit is fol lowing rubella vaccination. Am J Dis Child 125: 
526-530, 1973. 
Tobin, J.O.H.: Rubella vaccination of postpartum wo men and of adole­
scents i n the north-west of England. Can J Pub! Health 62: 64-67, 1971. 
Vaheri,  A., Vesik'ari ,  T., Oker-ESlom, N., Seppala, M ., Parkman, P.D., 
Veronell i ,  J. and Robbins, F.C.: Isolation of attenuated rubella-vac­
cine virus from hu man produ cts of conception and ute rine cervix. 
N Eng l J Me d 286: 1071-1074, 1972. 
Veale, H .: History of an epide mic of Röthein, with observations on i ts 
pathology. Edin Me d J 12: 404-414, 1866. 
Wallace, R.B. and Isacson , P.: Comparative t r ial of HPV-77 DE- 5 and 
RA 27/3 l ive-attenuated rubella vaccines. Am J Dis Child 124: 536-538, 
1972. 
Weibel, R.E., Stokes, J.Jr.,  Buynak, E.B. and Hil leman, M.R.: Live ru­
bella vaccines i n adults and ch i ldren. Am J Dis Child 118: 226-229, 
1969. 
Weibel, R.E., Stokes, J.Jr. ,  Buynak, E.B. and Hil lema n, M.R.: Influen­
ce o f age on c l inical response to HPV-77 duc k r ubella vaccine. JAMA 
222: 805-807, 1972. 
Weiler, T.H. and Neva , F.A.: Propagation in t issue culture of cytopa-
thic agents from pa tients with rubella-l ike i l lness. Proc Soc Exp B iol 
Med 1 11: 215-225, 1962. 
Wilkins, J.,  Leedom, J.M., Portnoy, B. and Salvatore, M.A.: Reinfec­
t ion with rubella virus despite l ive vaccine induced immunity. Am J 
Dis Child 118: 275-294, 1969. 
Wilkins, J.,  Leedom, J.M., Salvatore, M.A. and Portn oy, B.: Clinical 
rubella with arthrit is result ing from re infection. Ann Int Med 77: 
930-932, 1972. 
Wyll,  S.A., Herrmann, K .L., Abrutyn, E., Murphy, G.D. and Witte, J.J.: 
Rubella booster immunization. Serologic response to a second dose of 
vaccine. JAMA 216: 1451-1453, 1971. 
Wyll,  S.A. and Herr mann, K .L.: Inadvertent rubella vaccination of preg­
nant women. JAMA 225: 1472-1476, 1973. 
38 
På grund av upphovsrättsliga skäl kan vissa ingående delarbeten ej publiceras här. 
För en fullständig lista av ingående delarbeten, se avhandlingens början.
Due to copyright law limitations, certain papers may not be published here.
For a complete list of papers, see the beginning of the dissertation.
mmmåmm 
• i -  -  : ,  
MHI 

